Tags

Type your tag names separated by a space and hit enter

Tinea capitis: a treatment update.
Pediatr Ann. 2005 Mar; 34(3):191-200.PA

Abstract

Currently, many experts consider griseofulvin to be the drug of choice for tinea capitis. It is FDA approved for this indication, highly efficacious, and has an excellent long-term safety record. Nonetheless, there is now ample evidence documenting the efficacy and safety of other antifungal agents. Terbinafine, itraconazole, and fluconazole have been used off-label in the United States and United Kingdom for tinea capitis. Several studies have shown that short-term terbinafine, itraconazole, or fluconazole each are comparable in efficacy and safety to griseofulvin. High-dose griseofulvin is still the first-line therapy for tinea capitis in our practice, but a large-scale, multicenter trial of higher dose terbinafine is now ongoing, and positive efficacy and safety results from that study may lead to a change in our standard of care. Terbinafine, itraconazole, or fluconazole currently are used in patients who have either failed griseofulvin or developed adverse reactions to this medication. Families must be informed that these other antifungal agents are not FDA-approved for this indication when they are used. Guidelines for therapy with each of these agents are summarized in Table 5. In addition, the adjuvant use of antifungal shampoos is recommended for all patients in order to decrease the viability of fungal spores present on the hair, as well as for all household contacts to prevent infection or eliminate the carrier state.

Authors+Show Affiliations

Children's Hospital and Health Center and University of California San Diego Medical Center, San Diego, CA, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15792111

Citation

Roberts, Brandie J., and Sheila Fallon Friedlander. "Tinea Capitis: a Treatment Update." Pediatric Annals, vol. 34, no. 3, 2005, pp. 191-200.
Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann. 2005;34(3):191-200.
Roberts, B. J., & Friedlander, S. F. (2005). Tinea capitis: a treatment update. Pediatric Annals, 34(3), 191-200.
Roberts BJ, Friedlander SF. Tinea Capitis: a Treatment Update. Pediatr Ann. 2005;34(3):191-200. PubMed PMID: 15792111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tinea capitis: a treatment update. AU - Roberts,Brandie J, AU - Friedlander,Sheila Fallon, PY - 2005/3/29/pubmed PY - 2005/7/14/medline PY - 2005/3/29/entrez SP - 191 EP - 200 JF - Pediatric annals JO - Pediatr Ann VL - 34 IS - 3 N2 - Currently, many experts consider griseofulvin to be the drug of choice for tinea capitis. It is FDA approved for this indication, highly efficacious, and has an excellent long-term safety record. Nonetheless, there is now ample evidence documenting the efficacy and safety of other antifungal agents. Terbinafine, itraconazole, and fluconazole have been used off-label in the United States and United Kingdom for tinea capitis. Several studies have shown that short-term terbinafine, itraconazole, or fluconazole each are comparable in efficacy and safety to griseofulvin. High-dose griseofulvin is still the first-line therapy for tinea capitis in our practice, but a large-scale, multicenter trial of higher dose terbinafine is now ongoing, and positive efficacy and safety results from that study may lead to a change in our standard of care. Terbinafine, itraconazole, or fluconazole currently are used in patients who have either failed griseofulvin or developed adverse reactions to this medication. Families must be informed that these other antifungal agents are not FDA-approved for this indication when they are used. Guidelines for therapy with each of these agents are summarized in Table 5. In addition, the adjuvant use of antifungal shampoos is recommended for all patients in order to decrease the viability of fungal spores present on the hair, as well as for all household contacts to prevent infection or eliminate the carrier state. SN - 0090-4481 UR - https://www.unboundmedicine.com/medline/citation/15792111/Tinea_capitis:_a_treatment_update_ L2 - https://medlineplus.gov/childrenshealth.html DB - PRIME DP - Unbound Medicine ER -